Short Interest in Silexion Therapeutics Corp (NASDAQ:SLXN) Declines By 87.8%

Silexion Therapeutics Corp (NASDAQ:SLXN) saw a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 14,501 shares, a decline of 87.8% from the August 15th total of 119,287 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average daily volume of 257,490 shares, the short-interest ratio is presently 0.1 days.

Silexion Therapeutics Price Performance

Shares of NASDAQ:SLXN traded up $0.07 on Thursday, hitting $0.42. The company had a trading volume of 118,418,259 shares, compared to its average volume of 297,799. Silexion Therapeutics has a 1-year low of $0.34 and a 1-year high of $77.70. The stock has a 50 day moving average price of $1.44 and a 200 day moving average price of $6.26.

Silexion Therapeutics (NASDAQ:SLXN) last issued its quarterly earnings data on Saturday, August 15th. The company reported ($5.17) earnings per share for the quarter, beating the consensus estimate of ($21.20) by $16.03. Equities analysts expect that Silexion Therapeutics will post -45.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SLXN. Maxim Group downgraded shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Silexion Therapeutics has an average rating of “Hold”.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.